Trastuzumab deruxtecan (solution), CAS 1826843-81-5

Product Description: Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645./[2]Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518./[3]Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46./[4]Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.

CAS Number: 1826843-81-5

Molecular Weight: 153000 (average)

Compound Purity: 99.64

Research Area: Cancer

Solubility: H2O

Target: Antibody-Drug Conjugates (ADCs);EGFR

• Artikelnummer: MEXHY-138298-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-138298-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK